A strategic view of randomized trial design in low-incidence paediatric cancerR Sposto
Children s Cancer Group, University of Southern California School of Medicine, Arcadia 91066 6012, USA
Stat Med 18:1183-97. 1999
..From this viewpoint, insistence on large trials and stringent evidence for accepting new treatments can be counter-productive, in that likely gains in efficacy of treatment will be smaller over the long term...
- Cure model analysis in cancer: an application to data from the Children's Cancer Group
Richard Sposto
Children s Oncology Group and USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Stat Med 21:293-312. 2002
..Despite their reliance on explicit parametric forms, PCMs often provide a good description of cancer outcome, and are insensitive to lack of fit provided that follow-up is sufficient...
- Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group
R Sposto
Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Med Pediatr Oncol 37:432-41. 2001
..Therefore, in 1983 CCG initiated study CCG-503, a randomized trial of COMP vs. daunomycin-COMP (D-COMP) in children and adolescents with disseminated NLB NHL...
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical modelsW Cai
Division of Hematology Oncology, MS 119, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
Br J Cancer 103:1369-79. 2010
..Using neuroblastoma pre-clinical models, we determined whether the inhibition of MGMT by O(6)-benzylguanine (O6-BG) could enhance the anti-tumour activity of TMZ and irinotecan...
- Palpable breast cancers are inherently different from nonpalpable breast cancers
K A Skinner
Department of Surgery, Norris Comprehensive Cancer Center, Keck School of Medicine, The University of Southern California, Los Angeles 90033, USA
Ann Surg Oncol 8:705-10. 2001
..We examined the clinicopathologic profile of T1 cancers to determine whether palpable cancers are different from nonpalpable cancers...
- Breast cancer after augmentation mammoplasty
K A Skinner
Department of Surgery, Kenneth Norris, Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles 90033, USA
Ann Surg Oncol 8:138-44. 2001
..It is thought that implants interfere with breast cancer diagnosis and that cancers in women who have had breast augmentation carry a worse prognosis...
- Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma
Roger J Packer
Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
J Clin Oncol 24:4202-8. 2006
..To determine the event-free survival (EFS) and overall survival of children with average-risk medulloblastoma and treated with reduced-dose craniospinal radiotherapy (CSRT) and one of two postradiotherapy chemotherapies...
- Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
Mitchell S Cairo
Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
Blood 109:2736-43. 2007
..001). Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (B-ALL with or without CNS involvement)...
- Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Cameron K Tebbi
Children s Oncology Group, Statistics and Data Center, Arcadia, CA, USA
J Clin Oncol 25:493-500. 2007
..We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs)...
- Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group
Richard Sposto
Children s Center for Cancer and Blood Diseases, Children s Hospital Los Angeles, Los Angeles, CA 90027 6016, USA
J Clin Oncol 25:2070-7. 2007
....
- The problems and promise of central pathology review: development of a standardized procedure for the Children's Oncology Group
Lisa A Teot
Children s Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Pediatr Dev Pathol 10:199-207. 2007
..This article examines the historical usage and current status of the central pathology review process and the rationale and indications for its performance...
- Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors
Stergios Zacharoulis
Department of Pediatrics, The Royal Marsden Hospital, Sutton, Surrey, UK
Pediatr Blood Cancer 50:231-5. 2008
..Metastatic ependymoma is exceedingly rare at diagnosis with variable prognosis reported in the literature. The purpose of this study was to identify prognostic factors in children with metastatic ependymoma...
- Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report
Rodney R Miles
Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Br J Haematol 138:506-12. 2007
..These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL...
- Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and I
Jason Fangusaro
Children s Hospital Los Angeles, Los Angeles, California, USA
Pediatr Blood Cancer 50:312-8. 2008
....
Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocolsGirish Dhall
Childrens Hospital Los Angeles, Los Angeles, California, USA
Pediatr Blood Cancer 50:1169-75. 2008
..To determine the survival of infants and young children with non-metastatic medulloblastoma using intensive myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue (AuHCR)...
- Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
Mary Gerrard
Sheffield Children s Hospital, Sheffield, UK
Br J Haematol 141:840-7. 2008
..5 months, the 4 year event-free survival is 98.3% and overall survival is 99.2%. Children with resected localized B-NHL can be cured with minimal toxicity following two courses of low intensity treatment without IT chemotherapy...
- Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue
Stergios Zacharoulis
Department of Pediatric Hematology Oncology, Children s Hospital Los Angdes, Neural Tumors Program, Los Angles, CA 900 27, USA
Pediatr Blood Cancer 49:34-40. 2007
....
- Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933
Tobey J Macdonald
Department of Hematology Oncology, Children s National Medical Center, Washington, DC 20010, USA
Cancer 104:2862-71. 2005
..High-grade astrocytomas (HGA) carry a dismal prognosis and compose nearly 20% of all childhood brain tumors. The role of high-dose chemotherapy (HDCT) in the treatment of HGA remains unclear...
- Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08
Mark A Lones
Pathology Department, Children s Hospital of Orange County St Joseph Hospital, Orange, California, USA
J Pediatr Hematol Oncol 26:169-78. 2004
..Burkitt-like lymphomas were not associated with CMYC translocations. Further studies are warranted in larger cohorts of children and adolescents with Burkitt and Burkitt-like lymphomas...
- Expression of p53 and prognosis in children with malignant gliomas
Ian F Pollack
Department of Neurosurgery, University of Pittsburgh Medical Center and Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
N Engl J Med 346:420-7. 2002
..We investigated whether mutations in the TP53 gene or the degree of expression of p53 protein in high-grade gliomas is associated with progression-free survival in children with these tumors...
- Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report
Mark A Lones
Pathology Department, Children s Hospital of Orange County St Joseph Hospital, Orange, CA, USA
J Clin Oncol 20:2293-301. 2002
..NHL arising in bone is well recognized in adults but is less well characterized and infrequent in children and adolescents...
- Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort
Ian F Pollack
Departments of Neurosurgery, University of Pittsburgh Medical Center and the Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Neurosurgery 50:1238-44; discussion 1244-5. 2002
....
- Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group
Mark T Jennings
Vanderbilt Cancer Center, Nashville, TN, USA
J Clin Oncol 20:3431-7. 2002
..This Children's Cancer Group group-wide phase II trial evaluated the efficacy and toxicity of two chemotherapy arms administered before hyperfractionated external-beam radiotherapy (HFEBRT)...
- Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy
James B Nachman
Section of Pediatric Hematology Oncology, University of Chicago, Chicago, IL, USA
J Clin Oncol 20:3765-71. 2002
....
- Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer
Carol S Woo
Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Am J Surg 184:337-40. 2002
..The combination of the two factors is most meaningful in patients with 1 to 3 positive nodes...
- Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience
Mitchell S Cairo
Department of Pediatrics, Columbia University, New York, New York, USA
Am J Hematol 72:53-63. 2003
..Large numbers of patients treated with shorter and intense therapy are required to confirm these preliminary observations...
- Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers
Vani Sabesan
Indiana University School of Medicine, Indianapolis, USA
J Pediatr Hematol Oncol 25:109-13. 2003
..This study demonstrated the feasibility of PSPs to identify disease in staging and follow-up specimens, which could be used to develop strategies for MRD analysis in a larger setting...
- Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience
Mitchell S Cairo
Department of Pediatrics, Children s Hospital New York, Columbia University, New York, NY, USA
Br J Haematol 120:660-70. 2003
..001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy...
- Breast cancer: do specialists make a difference?
Kristin A Skinner
Department of Surgery, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California, USA
Ann Surg Oncol 10:606-15. 2003
..Many believe that breast cancer should be treated by specialists. We studied the effect of surgeon and hospital specialization on survival after breast cancer treatment in a large, well-defined patient population...
- High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors
Alberto Broniscer
Children's Cancer Group: New York University Medical Center, New York, NY, USA
Pediatr Blood Cancer 42:261-7. 2004
..006 and 0.01, respectively). CONCLUSIONS: Patients with recurrent cortical PNETs can be cured with this strategy. Surgical debulking before, and irradiation after HDC play an important role in treatment success...
